These companies control life-saving treatments that patients simply can't do without, creating unshakeable demand that supports consistent pricing power.
Patent-protected blockbuster drugs and high barriers to entry shield these pharmaceutical giants from competition, allowing sustained revenue growth through strategic price increases.
The coordinated price hikes across hundreds of medications demonstrate remarkable commercial confidence, suggesting these companies see strong demand ahead for their essential products.
Major drugmakers are demonstrating remarkable confidence by raising prices on over 350 medications, covering everything from cancer treatments to vaccines. This industry-wide action signals strong pricing leverage and market dominance, creating an opportunity to invest in companies that can translate essential drug portfolios into sustained revenue growth.
These pharmaceutical giants operate in markets with high barriers to entry and develop treatments for critical health conditions, creating non-discretionary demand. Their patent-protected blockbuster drugs and established market positions allow them to implement price increases whilst maintaining market share, offering potentially defensive characteristics during economic uncertainty.
Each company in this group has been handpicked for their proven ability to leverage pricing power through market-leading products and strong therapeutic portfolios. From Pfizer's vast drug portfolio to Vertex's near-monopoly in cystic fibrosis treatments, these firms have demonstrated the commercial confidence to drive revenue through strategic pricing decisions.
Following plans by major drugmakers to raise prices on hundreds of medications, the pharmaceutical industry is showcasing its significant pricing power. This development highlights an investment opportunity centered on established pharmaceutical companies capable of translating market dominance into revenue growth.
This basket's total market capitalisation is $3.78T and is anchored by several very large-cap constituents, giving it a generally stable, lower-risk profile.
PFE: $141.57B
GSK: $100.17B
SNY: $118.49B
Veröffentlicht am Januar 2
+5
Here are a few of the assets in this group. Create an account to unlock the full list.
Pfizer
PFE
Aktueller Kurs
$29.40
As a global pharmaceutical giant with a vast portfolio of widely used drugs and vaccines, Pfizer has significant leverage to implement price increases...
As a global pharmaceutical giant with a vast portfolio of widely used drugs and vaccines, Pfizer has significant leverage to implement price increases across its products.
SANOFI SPON ADR ECH REP 0.5 ORD SHS
SNY
Aktueller Kurs
$42.22
Sanofi's strong market positions in therapeutic areas like immunology and vaccines, along with its popular drug Dupixent, support its significant pric...
Sanofi's strong market positions in therapeutic areas like immunology and vaccines, along with its popular drug Dupixent, support its significant pricing power.
Join Nemo FREE today and unlock every stock
Es dauert nur 60 Sekunden.
Erfahren Sie alles über diesen Aktienkorb. Lesen Sie unseren ausführlichen Artikel zu seinen Risiken und seinem Potenzial.
Vollständige Analyse lesen
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
12 von 15 Werten dieser Gruppe werden von professionellen Analysten mit „Kaufen“ bewertet.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
